Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?

被引:199
|
作者
Otocka-Kmiecik, Aneta [1 ]
Mikhailidis, Dimitri P. [2 ]
Nicholls, Stephen J. [3 ]
Davidson, Michael [4 ]
Rysz, Jacek [5 ]
Banach, Maciej [1 ]
机构
[1] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Hypertens, PL-90549 Lodz, Poland
[2] UCL, Sch Med, Dept Clin Biochem, London, England
[3] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
[5] Med Univ Lodz, Chair Nephrol & Hypertens, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
关键词
Dyslipidemia; High density cholesterol; Inflammation; Lipids; Therapy; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CHOLESTERYL ESTER TRANSFER; TRANSFER PROTEIN-INHIBITION; ELEVATED OXIDATIVE STRESS; TYPE-2; DIABETIC-PATIENTS; ACUTE CORONARY SYNDROMES; HIGH-RISK; ANTIINFLAMMATORY PROPERTIES; ANTIOXIDANT PROPERTIES;
D O I
10.1016/j.plipres.2012.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
High density lipoprotein (HDL) has many properties, which contribute to its atheroprotective role. However, some recent clinical trials have identified subjects with the progression of atherosclerosis despite normal levels of HDL cholesterol. This raises the question if all subfractions of HDL have the same properties. Moreover, recent investigations have shown that both acute and chronic inflammation may lead to structural and functional changes of HDL, which render the particles proinflammatory. Although therapeutic agents that increase HDL levels are now quite well established it is not clear whether they influence HDL quality. We review the current state of knowledge on the properties of HDL and factors/therapeutic agents which may restrain the transformation of normal HDL into dysfunctional HDL (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:314 / 324
页数:11
相关论文
共 50 条
  • [1] Dysfunctional HDL as a Diagnostic and Therapeutic Target
    Smith, Jonathan D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (02) : 151 - 155
  • [2] Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention
    Ossoli, Alice
    Pavanello, Chiara
    Giorgio, Eleonora
    Calabresi, Laura
    Gomaraschi, Monica
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (09) : 1610 - 1630
  • [3] Dysfunctional HDL and atherosclerotic cardiovascular disease
    Robert S. Rosenson
    H. Bryan Brewer
    Benjamin J. Ansell
    Philip Barter
    M. John Chapman
    Jay W. Heinecke
    Anatol Kontush
    Alan R. Tall
    Nancy R. Webb
    Nature Reviews Cardiology, 2016, 13 : 48 - 60
  • [4] Dysfunctional HDL and atherosclerotic cardiovascular disease
    Rosenson, Robert S.
    Brewer, H. Bryan, Jr.
    Ansell, Benjamin J.
    Bartert, Philip
    Chapman, M. John
    Heinecke, Jay W.
    Kontush, Anatol
    Tall, Alan R.
    Webb, Nancy R.
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (01) : 48 - 60
  • [5] miR-33 as a Therapeutic Target for Raising HDL in Cardiovascular Disease
    Rayner, Katey
    Suarez, Yajaira
    Davalos, Alberto
    Temel, Ryan
    Esau, Christine
    Parathath, Saj
    Fisher, Edward
    Fernandez-Hernando, Carlos
    Moore, Kathryn J.
    CIRCULATION, 2010, 122 (21)
  • [6] Ferroptosis as a novel therapeutic target for cardiovascular disease
    Wu, Xiaoguang
    Li, Yi
    Zhang, Shuchen
    Zhou, Xiang
    THERANOSTICS, 2021, 11 (07): : 3052 - 3059
  • [7] Dysfunctional HDL Diagnostic Metrics for Cardiovascular Disease Risk Stratification: Are we Ready to Implement in Clinics?
    Kempegowda, Swetha N.
    Sugur, Kavya
    Thimmulappa, Rajesh K.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2025, 18 (01) : 169 - 184
  • [8] Telomere shortening: a diagnostic tool and therapeutic target for cardiovascular disease?
    Muller, Majon
    Rabelink, Ton J.
    EUROPEAN HEART JOURNAL, 2014, 35 (46) : 3245 - 3247
  • [9] Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease
    Broekhuizen, Lysette N.
    Mooij, Hans L.
    Kastelein, John J. P.
    Stroes, Erik S. G.
    Vink, Hans
    Nieuwdorp, Max
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (01) : 57 - 62
  • [10] Lipoprotein[a]: a novel therapeutic target for cardiovascular disease management
    Ahmad, Muhammad
    Khan, Malik W. Z.
    Ali, Aizaz
    CARDIOLOGY IN THE YOUNG, 2024, 34 (07) : 1616 - 1617